Identification of genomic and molecular traits that present therapeutic vulnerability to HGF-targeted therapy in glioblastoma-Reference-Cited by-同舟云学术

Identification of genomic and molecular traits that present therapeutic vulnerability to HGF-targeted therapy in glioblastoma

Published:2018-06-23 Issue:2 Volume:21 Page:222-233
ISSN:1522-8517
Container-title:Neuro-Oncology
language:en
Short-container-title:

Author:

Sa Jason K¹²,Kim Sung Heon¹³,Lee Jin-Ku¹²,Cho Hee Jin¹²,Shin Yong Jae¹²⁴,Shin Hyemi¹⁵,Koo Harim⁵,Kim Donggeon¹²,Lee Mijeong¹⁵,Kang Wonyoung⁶,Hong Sung Hee⁷⁸,Kim Jung Yong⁸,Park Young-Whan⁸,Song Seong-Won⁹,Lee Song-Jae⁹,Joo Kyeung Min³⁵,Nam Do-Hyun¹⁵⁴

Affiliation:

1. Institute for Refractory Cancer Research, Samsung Medical Center, Seoul, Republic of Korea

2. Research Institute for Future Medicine, Samsung Medical Center, Seoul, Republic of Korea

3. Department of Anatomy and Cell Biology, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

4. Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

5. Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Seoul, Republic of Korea

6. The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, USA

7. Hanmi Pharmaceutical Co. Ltd., Songpa-Gu, Seoul, Republic of Korea

8. National OncoVenture, National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea

9. Yooyoung Pharmaceutical Co. Ltd., Guro-gu, Seoul, Republic of Korea

Funder

Ministry of Health & Welfare, Republic of Korea

National OncoVenture/National Cancer Center

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Neurology (clinical),Oncology

Link